{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:23:49Z","timestamp":1786983829021,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier","isbn-type":[{"value":"9780443223143","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.pmbts.2023.12.014","type":"book-chapter","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T12:19:10Z","timestamp":1706185150000},"page":"181-196","source":"Crossref","is-referenced-by-count":3,"title":["RNA therapeutics for metabolic disorders"],"prefix":"10.1016","member":"78","reference":[{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.014_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41569-020-00465-5","article-title":"Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging","volume":"18","author":"Ng","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/bs.pmbts.2023.12.014_bib2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1152\/physrev.00002.2020","article-title":"Developmental origins of metabolic diseases","volume":"101","author":"Hoffman","year":"2021","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.014_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Collaborators","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmbts.2023.12.014_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.reprotox.2016.10.001","article-title":"Metabolism disrupting chemicals and metabolic disorders","volume":"68","author":"Heindel","year":"2017","journal-title":"Reprod Toxicol"},{"issue":"2","key":"10.1016\/bs.pmbts.2023.12.014_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10517-021-05191-7","article-title":"Oxidative stress: pathogenetic role in diabetes mellitus and its complications and therapeutic approaches to correction","volume":"171","author":"Darenskaya","year":"2021","journal-title":"Bull Exp Biol Med"},{"issue":"6","key":"10.1016\/bs.pmbts.2023.12.014_bib6","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.dsx.2018.05.004","article-title":"An update on physical health and economic consequences of overweight and obesity","volume":"12","author":"Chu","year":"2018","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/bs.pmbts.2023.12.014_bib7","unstructured":"European Association for the Study of Obesity (EASO). Obesity Facts & Figures; 2018. Available from: \u3008http:\/\/easo.org\/education-portal\/obesity-facts-figures\/\u3009."},{"key":"10.1016\/bs.pmbts.2023.12.014_bib8","unstructured":"World Health Organization. Global Health Observatory (GHO) data: Obesity; 2018. [01\/08\/2023]; Available from: \u3008http:\/\/www.who.int\/gho\/ncd\/risk_factors\/obesity_text\/en\/\u3009."},{"issue":"5","key":"10.1016\/bs.pmbts.2023.12.014_bib9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000480525","article-title":"Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies \u2013 EASO can lead the way","volume":"10","author":"Leitner","year":"2017","journal-title":"Obes Facts"},{"issue":"3","key":"10.1016\/bs.pmbts.2023.12.014_bib10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s13679-020-00389-8","article-title":"Outcomes in bariatric and metabolic surgery: an updated 5-year review","volume":"9","author":"Roth","year":"2020","journal-title":"Curr Obes Rep"},{"issue":"5","key":"10.1016\/bs.pmbts.2023.12.014_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000355480","article-title":"Interdisciplinary European Guidelines on metabolic and bariatric surgery","volume":"6","author":"Fried","year":"2013","journal-title":"Obes Facts"},{"issue":"12","key":"10.1016\/bs.pmbts.2023.12.014_bib12","first-page":"831","article-title":"Diagnosis, treatment, and prevention of gout","volume":"90","author":"Hainer","year":"2014","journal-title":"Am Fam Physician"},{"issue":"6","key":"10.1016\/bs.pmbts.2023.12.014_bib13","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/bs.pmbts.2023.12.014_bib14","doi-asserted-by":"crossref","first-page":"16080","DOI":"10.1038\/nrdp.2016.80","article-title":"Mitochondrial diseases","volume":"2","author":"Gorman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/bs.pmbts.2023.12.014_bib15","article-title":"The role of mitochondria in Duchenne muscular dystrophy","volume":"72","author":"Budzinska","year":"2021","journal-title":"J Physiol Pharmacol"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.014_bib16","article-title":"Natural nanoparticles: a particular matter inspired by nature","volume":"7","author":"Griffin","year":"2017","journal-title":"Antioxidants (Basel)"},{"issue":"6","key":"10.1016\/bs.pmbts.2023.12.014_bib17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.014_bib18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.014_bib19","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1039\/D0CS01261K","article-title":"Targeting RNA with small molecules: from fundamental principles towards the clinic","volume":"50","author":"Falese","year":"2021","journal-title":"Chem Soc Rev"},{"issue":"10","key":"10.1016\/bs.pmbts.2023.12.014_bib20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2014developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/bs.pmbts.2023.12.014_bib21","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1002\/emmm.201202287","article-title":"Gene therapy on the move","volume":"5","author":"Kaufmann","year":"2013","journal-title":"Embo Mol Med"},{"issue":"23","key":"10.1016\/bs.pmbts.2023.12.014_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24234229","article-title":"Aptamers: a review of their chemical properties and modifications for therapeutic application","volume":"24","author":"Adachi","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/bs.pmbts.2023.12.014_bib23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/190576a0","article-title":"An unstable intermediate carrying information from genes to ribosomes for protein synthesis","volume":"190","author":"Brenner","year":"1961","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2023.12.014_bib24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/190581a0","article-title":"Unstable ribonucleic acid revealed by pulse labelling of Escherichia coli","volume":"190","author":"Gros","year":"1961","journal-title":"Nature"},{"issue":"15","key":"10.1016\/bs.pmbts.2023.12.014_bib25","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.014_bib26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11427-022-2171-2","article-title":"RNA therapeutics: updates and future potential","volume":"66","author":"Zhang","year":"2023","journal-title":"Sci China Life Sci"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.014_bib27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ymthe.2019.03.002","article-title":"mRNA: a novel avenue to antibody therapy?","volume":"27","author":"Schlake","year":"2019","journal-title":"Mol Ther"},{"issue":"6669","key":"10.1016\/bs.pmbts.2023.12.014_bib28","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"7","key":"10.1016\/bs.pmbts.2023.12.014_bib29","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-021-01511-3","article-title":"Givosiran: a review in acute hepatic porphyria","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/bs.pmbts.2023.12.014_bib30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/bs.pmbts.2023.12.014_bib31","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/bs.pmbts.2023.12.014_bib33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.014_bib34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/bs.pmbts.2023.12.014_bib36","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"10.1016\/bs.pmbts.2023.12.014_bib37","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: first global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/bs.pmbts.2023.12.014_bib38","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","article-title":"Volanesorsen: first global approval","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/bs.pmbts.2023.12.014_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/bs.pmbts.2023.12.014_bib40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-pharmtox-010716-104558","article-title":"Aptamers as therapeutics","volume":"57","author":"Nimjee","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/bs.pmbts.2023.12.014_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/bs.pmbts.2023.12.014_bib42","first-page":"67910","article-title":"Inotersen to treat polyneuropathy associated with hereditary transthyretin (hATTR) amyloidosis","volume":"10","author":"Robinson","year":"2022","journal-title":"Health Psychol Res"},{"issue":"6","key":"10.1016\/bs.pmbts.2023.12.014_bib43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/bs.pmbts.2023.12.014_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24552","article-title":"The promising novel therapies for familial hypercholesterolemia","volume":"36","author":"Chen","year":"2022","journal-title":"J Clin Lab Anal"},{"issue":"7","key":"10.1016\/bs.pmbts.2023.12.014_bib45","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/gutjnl-2019-318269","article-title":"Messenger RNA therapy for rare genetic metabolic diseases","volume":"68","author":"Berraondo","year":"2019","journal-title":"Gut"},{"key":"10.1016\/bs.pmbts.2023.12.014_bib46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0065-3101(24)00072-0","article-title":"Urea cycle disorders: diagnosis, pathophysiology, and therapy","volume":"43","author":"Brusilow","year":"1996","journal-title":"Adv Pediatr"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.014_bib47","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10545-012-9546-2","article-title":"Ammonia toxicity to the brain","volume":"36","author":"Braissant","year":"2013","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.014_bib48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/bs.pmbts.2023.12.014_bib49","article-title":"Advancements in mRNA encoded antibodies for passive immunotherapy","volume":"9","author":"Deal","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/bs.pmbts.2023.12.014_bib50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/nat.2022.0036","article-title":"Translational pharmacokinetic\/pharmacodynamic model for mRNA-3927, an investigational therapeutic for the treatment of propionic acidemia","volume":"33","author":"Attarwala","year":"2023","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"10.1016\/bs.pmbts.2023.12.014_bib51","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/bs.pmbts.2023.12.014_bib52","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/cts.12624","article-title":"Targeting RNA: a transformative therapeutic strategy","volume":"12","author":"Yin","year":"2019","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/bs.pmbts.2023.12.014_bib53","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis"},{"issue":"15","key":"10.1016\/bs.pmbts.2023.12.014_bib54","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1021\/ja00718a039","article-title":"Nucleoside phosphorothioates","volume":"92","author":"Eckstein","year":"1970","journal-title":"J Am Chem Soc"},{"issue":"7","key":"10.1016\/bs.pmbts.2023.12.014_bib55","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/jm00059a007","article-title":"Uniformly modified 2\u2032-deoxy-2\u2032-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets","volume":"36","author":"Kawasaki","year":"1993","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/bs.pmbts.2023.12.014_bib56","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/nar\/29.10.2163","article-title":"Hybridization of 2\u2032-ribose modified mixed-sequence oligonucleotides: thermodynamic and kinetic studies","volume":"29","author":"Sabahi","year":"2001","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10.1016\/bs.pmbts.2023.12.014_bib57","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1248\/cpb.13.1273","article-title":"Synthesis of 2\u2032-O-methyluridine, 2\u2032-O-methylcytidine and their relating compounds","volume":"13","author":"Furukawa","year":"1965","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"1","key":"10.1016\/bs.pmbts.2023.12.014_bib58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"}],"container-title":["Progress in Molecular Biology and Translational Science","RNA Therapeutics Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117323001965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117323001965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:04:00Z","timestamp":1762560240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117323001965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443223143"],"references-count":56,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2023.12.014","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}